FDA Brief

Warning letters Drugs

FDA warning letter to

HealthPartners Neuroscience Center Research and Innovation

MediumIssued May 19Posted Jun 2Center for Drug Evaluation and Research (CDER)

FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

What happened

FDA inspected HealthPartners Neuroscience Center Research and Innovation in Saint Paul, Minnesota, from March 17 to 21, 2025, reviewing its role as the testing laboratory for two nonclinical (animal) studies of an investigational drug. Investigators found the site never tested the drug mixtures it dosed animals with, that the quality assurance unit missed errors in the final study report, that equipment could not produce required blood test results, and that basic written procedures were missing. FDA reviewed the company's April 11 and June 13, 2025 responses and found them insufficient in detail.

What FDA found

  1. The site mixed the test article with sterile water and dosed animals without ever testing whether the mixture was uniform or at the intended concentration.

    21 CFR 58.31(d) and 21 CFR 58.113(a)(1)
  2. The quality assurance unit did not catch that the final study report left out two rat deaths, swapped which dose group had which clinical observations, and gave the wrong day for another death.

    21 CFR 58.35(b)(6)
  3. Equipment at the site could not produce required hematology and serum chemistry results for rats and rabbits, and was not cross-validated to show it could analyze rat or rabbit blood.

    21 CFR 58.31(e) and 21 CFR 58.61
  4. The site had no written standard operating procedures for handling test articles, observing test animals, running laboratory tests, handling dead or dying animals, or collecting and identifying specimens.

    21 CFR 58.81(a) and 58.81(b)

What FDA wants

FDA asks the company to write back within 15 business days describing the actions it has taken to prevent similar violations, including training and audit details. FDA says failure to address the matter adequately may lead to regulatory action without further notice.

Who should pay attention

  • sponsors and sponsor-investigators who rely on outside laboratories for nonclinical studies
  • contract research organizations and testing facilities running animal studies under good laboratory practice rules
  • quality assurance units that review nonclinical study reports

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Lovelace Biomedical Research Institute

    Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.

    Medium
  2. Vedic Lifesciences Pvt. Ltd.

    FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

    Medium
  3. Palamur Biosciences Private Limited

    FDA warns Palamur Biosciences over GLP violations in medical device safety testing and inadequate corrective actions.

    High risk
  4. Jiangsu Kerbio Medical Technology Group Co.

    FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.

    High risk